FABP4 and atherosclerosis: FABP4 has been demonstrated to act as an adipokine for the development of insulin resistance in the liver [14], suppression of cardiomyocyte contraction [19] and the development of atherosclerosis [20], supporting inhibition of endothelial nitric oxide synthase activity in endothelial cells [21], and proliferation and migration of vascular smooth muscle cells [22].